Treatment of hepatorenal syndromes (HRSs) is currently based on vasopressin analogs. The aim of this pilot study was to evaluate the efficacy and safety of noradrenalin (NA) in the treatment of type 1 HRS. Between 1998 and 2000, 12 consecutive patients with type 1 HRS (7 men, 5 women; mean age, 54 ؎ 11 years; mean Child-Pugh score, 11.3 ؎ 1.7) were treated with intravenous NA (0.5-3 mg/h), in combination with intravenous albumin and furosemide. NA was given for 10 ؎ 3 days, at a mean dose of 0.8 ؎ 0.3 mg/h. Reversal of HRS was observed in 10 of 12 patients (83%; 95% confidence interval, 52%-98%) after a median of 7 days (range, 5-10 days). Serum creatinine levels fell from 358 ؎ 161 to 145 ؎ 78 mol/L (P < .001), creatinine clearance rose from 13 ؎ 9 to 40 ؎ 15 mL/min (P ‫؍‬ . H epatorenal syndrome (HRS) is a frequent and major complication of end-stage cirrhosis. It is considered as a functional renal failure caused by marked renal vasoconstriction, related to peripheral (mainly splanchnic) arterial vasodilation. 1 Type 1 HRS usually occurs in patients with end-stage liver disease and shows a poor prognosis. The median survival time is about 10 days. It is defined as rapidly progressive renal failure with a 50% reduction in initial creatinine clearance to below 20 mL/min within 15 days. 2 Type 2 HRS occurs instead in patients with refractory ascites and is characterized by moderate and more stable impairment of renal function. Liver transplantation is the only treatment to improve survival in patients with type I HRS 3 ; however, because of the very poor prognosis of type 1 HRS and because of organ shortage, a donor is usually not found quickly enough to avoid death. HRS management thus focuses on improving renal function and thereby extending survival pending liver transplantation. This has recently been addressed by assessing the effects of vasoconstrictors that, combined with plasma expanders, restore the collapse of systemic vascular resistances (SVRs) underlying HRS. 1,4-9 Thus, vasopressin analogs such as ornipressin 4-6 and terlipressin 7-9 improve renal perfusion and glomerular filtration in patients with HRS by inducing vasoconstriction of the splanchnic circulation.
H epatorenal syndrome (HRS) is a frequent and major complication of end-stage cirrhosis. It is considered as a functional renal failure caused by marked renal vasoconstriction, related to peripheral (mainly splanchnic) arterial vasodilation. 1 Type 1 HRS usually occurs in patients with end-stage liver disease and shows a poor prognosis. The median survival time is about 10 days. It is defined as rapidly progressive renal failure with a 50% reduction in initial creatinine clearance to below 20 mL/min within 15 days. 2 Type 2 HRS occurs instead in patients with refractory ascites and is characterized by moderate and more stable impairment of renal function. Liver transplantation is the only treatment to improve survival in patients with type I HRS 3 ; however, because of the very poor prognosis of type 1 HRS and because of organ shortage, a donor is usually not found quickly enough to avoid death. HRS management thus focuses on improving renal function and thereby extending survival pending liver transplantation. This has recently been addressed by assessing the effects of vasoconstrictors that, combined with plasma expanders, restore the collapse of systemic vascular resistances (SVRs) underlying HRS. 1, [4] [5] [6] [7] [8] [9] Thus, vasopressin analogs such as ornipressin [4] [5] [6] and terlipressin [7] [8] [9] improve renal perfusion and glomerular filtration in patients with HRS by inducing vasoconstriction of the splanchnic circulation.
Noradrenalin (NA) is a catecholamine with predominantly ␣-adrenergic activity. Given its vasoconstricting effects in venous and arterial systems, and its limited action on the myocardium, it is currently the drug of choice for vasoplegic shock. These pharmacologic properties suggest that NA might also counteract the collapse in SVRs leading to HRS. After a case report of successful treatment of HRS with a combination of NA and dopamine, 10 we conducted a pilot study to assess the safety and efficacy of intravenous NA in patients with type 1 HRS.
Patients and Methods
Patients. This prospective study was conducted in the intensive care unit of the Liver Unit of our institution from May 1998 to July 2000. All patients presenting with cirrhosis and renal failure consistent with type 1 HRS 1 were considered for inclusion. The HRS was diagnosed by using the major criteria proposed by the International Ascites Club, 1 namely: (1) a low glomerular filtration rate as assessed by serum creatinine level greater than 132 mmol/L or creatinine clearance below 40 mL/min; (2) absence of shock, ongoing bacterial infection, fluid losses, or treatment with nephrotoxic drugs; (3) no sustained improvement of renal function after oral diuretic withdrawal and plasma volume expansion; and (4) proteinuria less than 500 mg/d and no ultrasonographic evidence of parenchymal renal disease or urinary tract obstruction. Type 1 HRS was defined as a rapidly progressive reduction in renal function based on one of the following criteria: (1) doubling of the initial serum creatinine level to a level greater than 230 mol/L, and (2) a 50% reduction in the initial 24-hour creatinine clearance level to a level lower than 20 mL/min in less than 2 weeks. 1 Exclusion criteria were as follows: (1) improvement in renal function after central blood volume expansion, (2) history of infection within the past week, (3) contraindications to NA (history of coronary disease, obstructive cardiomyopathy, ventricular arrhythmia, or obliterative arterial disease of the lower limbs), and (4) a Child-Pugh score greater than 13 (i.e., 14 or 15).
Nineteen patients were considered for inclusion. Seven patients were considered ineligible for the following reasons: improvement in renal function during blood volume expansion (5 cases), occurrence of spontaneous bacterial peritonitis (1 case), and deterioration of the Child-Pugh score to C14 during the observation period (1 case). Twelve patients were finally enrolled in the study. The diagnosis of cirrhosis was based on histologic data in 5 patients and on a combination of clinical, biochemical, and sonographic findings in the remaining 7 patients. The clinical features of the 12 patients at screening are summarized in Table 1 . In 2 cases, NA was initiated after terlipressin failure, after a wash-out period of 48 hours. In these 2 patients, terlipressin had been initiated in another institution, before referral to our center. Informed written consent was obtained from each patient, and the study protocol conformed to the ethical guidelines of the 1975 Helsinki Declaration.
Study Design. On suspicion of type 1 HRS, patients were transferred to the intensive care unit of our department. A central venous line and urinary bladder catheter were inserted and continuous cardiac monitoring was initiated. Central venous pressure (CVP), urine output, and arterial blood pressure (by using a noninvasive technique) were measured every 4 hours. During the preinclusion phase, patients received human albumin infusion (20 g/100 mL; Laboratoires LFB, Les Ulis, France) to maintain CVP above 4 mm Hg. Thereafter, intravenous boluses of 120 mg of furosemide were infused to maintain CVP below 10 mm Hg and urine output above 100 mL/4 h. The efficacy of this first-line treatment was assessed after 48 hours; failure was defined as daily urine output lower than 600 mL and/or lack of improvement in the serum creatinine level or creatinine clearance. Patients in failure at 48 hours received a continuous infusion of NA (Levophed; Laboratoire Aguettant, Lyon, France) at an initial dose of 0.5 mg/h, designed to achieve an increase in mean arterial pressure (MAP) of at least 10 mm Hg or an increase in 4-hour urine output to more than 200 mL. When one of these goals was not reached, the NA dose was increased every 4 hours in steps of 0.5 mg/h, up to the maximum dose of 3 mg/h. Efficacy was assessed on serum creatinine and creatinine clearance, both measured daily. A 30% increase in creatinine clearance or a 30% decrease of serum creatinine were considered a positive response to NA. NA was administered either until HRS reversal (serum creatinine level below 133 mol/L and/or creatinine clearance above 40 mL/min), or for a maximum of 15 days. NA doses were subsequently tapered to 0 over 3 days. During NA treatment, albumin and furosemide administration was pursued to maintain CVP between 4 and 10 mm Hg. In addition, patients underwent a 100% compensation of their diuresis and urine sodium/potassium outputs on a 4-hour basis. In case of HRS relapse after NA withdrawal, NA was reintroduced as described earlier. Study Parameters. The following parameters were recorded 3 days before NA initiation (day Ϫ3), at baseline (day 0), and on days 1, 3, 5, and 10 after NA initiation: systolic, diastolic, and MAP, heart rate, CVP, daily urine output, daily urinary sodium excretion, urine creatinine, serum sodium and creatinine (mol/L) levels, creatinine clearance, serum bilirubin (mol/L), and the prothrombin time (%).
The active renin (Renin III generation; Pasteur Diagnostics, Sanofi-Pasteur, France) and aldosterone plasma concentrations (Coat-a-count Aldosterone; Behring Diagnostics, Paris-La Défense, France) were measured on days 0, 3, and 5 in 9 patients. SVRs were estimated in 6 of these 9 patients by transthoracic echocardiography at baseline and on day 5. SVRs were calculated according to the following formula: 11
Adverse events were recorded daily and assessed for their relation to NA administration.
Statistical Analysis. Continuous variables are expressed as means Ϯ 1 SD. Comparisons were made by using nonparametric tests (Friedmann's 2-way ANOVA for repeated measures, and the Wilcoxon rank test for paired data). P values less than .05 and .01 were considered statistically significant for multiple and pairwise comparisons, respectively.
Results
During the 48-hour preinclusion phase, renal function deteriorated significantly despite plasma volume expansion and diuretics. Serum creatinine levels rose from 240 Ϯ 99 mol/L (2.6 Ϯ 1.1 mg/dL) at screening (day Ϫ2) to 358 Ϯ 161 mol/L (3.9 Ϯ 1.8 mg/dL) at baseline (day 0) ( Table 2) .
NA was given at a mean dose of 0.8 Ϯ 0.3 mg/h (range, 0.5-3.0 mg/h) for a mean duration of 10 Ϯ 3 days (range, 5-15 d). All 12 patients completed the treatment. In one patient, NA was withdrawn on day 5 because renal function had normalized. HRS reversal was observed in 10 of 12 patients (83%; 95% confidence interval, 52%-98%) ( Fig. 1) , including the 2 patients who had not responded to terlipressin.
Reversal of HRS occurred after a median of 7 days (range, 5-10 d). The effects of NA on renal function, hemodynamic parameters, vasoactive substances, and liver function are summarized in Tables 2 and 3. NA initiation was followed rapidly by a significant improvement in urine output, urinary sodium excretion, serum creatinine, creatinine clearance, and the serum sodium concentration (Table 2) . Changes in urine output, sodium excretion, and creatinine clearance were significant by day 1. Improvements in serum creatinine and serum sodium concentrations were significant by day 3. Regression of renal failure was associated both with a marked increase in MAP (significant by day 1), and with a significant reduction in renin-aldosterone system activity (Table 3) . It should be noted that CVP did not change significantly despite the increase in MAP. Estimation of SVR in 6 patients showed a slight (nonsignificant) increase in SVR. During NA treatment the prothrombin time and serum bilirubin concentration did not change significantly, whereas alanine transaminase activity decreased significantly ( Table 2) .
The mean daily doses of furosemide and albumin were significantly higher before NA initiation than during NA infusion (352 Ϯ 420 mg/d vs. 105 Ϯ 145 mg/d, P Ͻ .05, and 65 Ϯ 34 g/d vs. 22 Ϯ 15 g/d, P ϭ .003, respectively).
Adverse Effects. Two patients had an episode of chest pain. In the first case, the pain occurred during 0.5 mg/h NA. Cardiac investigations were normal. NA was withdrawn for 24 hours and reinitiated at the same dose without chest-pain recurrence; the patient subsequently underwent successful liver transplantation. In the second case, the NA dose was 1.5 mg/h, and the transthoracic echocardiogram showed hypokinesia of the left ventricular apex, which disappeared on NA withdrawal. Thirty-six hours later, NA was reinitiated at 0.5 and then 1 mg/h for 7 days without pain recurrence; HRS reversal was subsequently achieved in both patients.
Follow-up. Three patients underwent liver transplantation at 10, 40, and 70 days after study completion. At transplantation, serum creatinine levels in these 3 patients were 73, 106, and 81 mol/L, respectively. Four patients who were ineligible for liver transplantation had prolonged survival and returned to a more stable status of refractory ascites. After a median of 332 days (range, 180-450 days), the median serum creatinine level in these 4 patients was 90 mol/L (range, 79-120 mol/L). There were 5 early deaths, occurring a median of 3 days after study completion (range, 0-12 days). Three of these 5 deaths occurred despite improved renal function on NA. The causes of death were end-stage liver failure in 4 cases. In the last case, death was precipitated by cerebral hemorrhage occurring 12 days after the end of the study, in a patient with end-stage liver failure. Cerebral hemorrhage was not considered related to the study drug because blood pressure was in the normal range before and at the time of bleeding. It was considered the consequence of major coagulation defects and thrombocytopenia. The 2-month actuarial probability of survival after NA initiation was 50% without transplantation and 58% with transplantation (Fig. 2) .
Discussion
Because HRS is the ultimate consequence of peripheral (mainly splanchnic) arterial vasodilation, 1 vasopressor agents have been proposed for the treatment of this condition. Indeed, nonselective V1 vasopressin agonists induce vasoconstriction of the splanchnic circulation and improve circulatory function in this setting, leading to an increase in renal perfusion and the glomerular filtration rate. [4] [5] [6] [7] [8] [9] NA is an ␣-adrenergic agonist with powerful vasoconstrictive activity for both venous and arterial territories. The current study shows that this drug is also effective in reversing type 1 HRS, an effect that was obtained in 10 (83%) of the 12 patients studied. This efficacy rate is similar to that obtained in a recent study with terlipressin, which reversed HRS in 7 of 9 patients. 9 However, it should be stressed that the terlipressin study included patients with both type I and type II HRS, and that the efficacy of terlipressin in type I HRS therefore needs to be further clarified. Although NA was administered in combination with albumin infusion and furo- semide, the role of NA was clearly predominant: (1) renal function did not improve during the preinclusion phase of the study, when albumin and furosemide were given without NA, which is in keeping with previous reports that diuretics and albumin alone do not reverse HRS 12 ; (2) NA administration was followed by a marked and rapid improvement in renal function, reaching statistical significance within 24 hours; (3) initiation of NA treatment was followed by a significant increase in MAP, associated with a marked reduction in renin-aldosterone system activity; and (4) the reversal of HRS was not caused by a parallel improvement in liver function because the prothrombin time and serum bilirubin concentration did not change significantly during NA administration. One can therefore assume that NA-induced vasoconstriction was the triggering mechanism leading to HRS reversal. However, one cannot exclude the possibility that albumin infusion added to the efficacy of NA because it has recently been suggested that the use of albumin is essential to ensure the efficacy of vasopressin derivatives in the treatment of HRS. 13 Treatment of HRS with ␣-adrenergic agonists has already been reported. The use of NA in cirrhotic patients was first attempted by Hecker and Sherlock. 14 In their study, 3 of 9 patients with end-stage liver disease, hypotension, and renal failure received NA. NA was associated with an increase in blood pressure in every case and improved urine output in 1 patient. The other 2 patients died 24 hours after NA initiation, and no firm conclusions on NA efficacy could be drawn from this study. More recently, reversal of type I HRS was reported in a patient receiving NA in combination with dopamine for 3 days. 10 An increase in plasma-renin activity has been reported after short-term NA infusion in patients with HRS, suggesting a vasoconstrictive effect on the renal artery. 15 This was not the case in our study, as shown by the marked reduction in plasma-active renin and aldosterone concentrations during NA treatment, matching the improvement in renal function. It should also be stressed that in a previous study including 9 cirrhotic patients with ascites (but without renal failure), NA infusion was followed by a decrease in aldosterone secretion in 6 cases and a significant increase in urinary sodium excretion in 3 cases. 16 This suggests that the hemodynamic benefit derived from NA-induced peripheral vasoconstriction probably predominates over the action of NA on the renal artery and results in improved renal perfusion.
Another ␣-adrenergic agonist, midodrine, has also been tested in patients with HRS. 17, 18 Acute oral monotherapy with 15 mg of midodrine only slightly improved systemic hemodynamics and failed to improve renal function in patients with type 2 HRS. 17 However, when given in combination with octreotide (an inhibitor of endogenous vasodilators release) and albumin, midodrine administration was associated with a significant improvement in renal function in 5 patients with type I HRS. 18 Taken together, these results suggest that ␣-adrenergic agonists are able to improve renal perfusion in patients with HRS; however, intravenous NA probably exerts a more powerful vasocontrictive action than oral midodrine and could therefore be used as singleagent therapy to reverse HRS, whereas midodrine may require concomitant vasodilator inhibition to achieve clinical efficacy. It could also be that octreotide has no effect on renal function; the improvement of renal function in this latter study could just be owing to the combination of midodrine and albumin.
The beneficial effect of NA in patients with type I HRS may appear paradoxical. Indeed, the pathogenesis of renal vasoconstriction in HRS involves sympathetic autonomous system hyperactivity, as indicated by the marked increase in plasma levels of NA in patients with HRS. In this respect, the efficacy of vasopressin analogs may also appear paradoxic because serum antidiuretic hormone concentrations are also markedly increased in HRS. Sim- ilarly, infusion of angiotensin, a potent vasopressor, to cirrhotic patients with ascites is not always associated with an increase in aldosterone secretion and can even induce a paradoxical increase in natriuresis, which is probably related to an increase in arterial pressure. 16 Taken together, these results suggest that, in HRS, the overactivity of endogenous vasoconstrictor systems cannot counteract the deleterious effects of splanchnic vasodilation and the associated reduction in SVRs. This could be caused, at least in part, by impaired arterial reactivity to vasopressors in cirrhotic patients. 19 Therefore, pharmacologic doses of vasoconstrictors such as vasopressin derivatives and NA may be necessary to restore SVR, thereby leading to down-regulation of the endogenous vasopressor systems and improved renal perfusion. This hypothesis is supported by studies showing a reduction in norepinephrine concentrations in parallel to the improvement in MAP and renal function in patients treated with ornipressin or terlipressin 5, 9 ; it is also supported by the reduction in antidiuretic hormone concentrations in patients treated with midodrine. 18 Despite the improvement in renal perfusion during NA treatment, we found no significant change in SVR in this study. However, the marked reduction in renin-angiotensin-system activity and the significant increase in MAP during NA administration clearly indicate that NA has a vasopressive action in HRS. We therefore assume that the lack of significant improvement in SVR during treatment was caused either by the small number of patients who underwent the full hemodynamic study, or by a lack of sensitivity of the technique we used to measure SVR. Indeed, the severe coagulation disorders of our patients precluded sustained direct assessment of hemodynamic parameters with a Swann-Ganz catheter. Hemodynamic parameters were therefore measured indirectly, on the basis of cardiac output measurement by transthoracic duplex-Doppler, MAP calculation, and CVP monitoring. Further studies are therefore required to assess the hemodynamic effects of NA in patients with HRS. In any case, it must be underlined that a simple method for monitoring SVR in patients with HRS would probably be very useful to manage vasoactive treatments.
In our study, NA infusion was associated with a marked increase in urinary sodium excretion. Such an effect has not been reported in studies of vasopressin analogs 4-9 but is probably not specific to NA, rather it might be related to the use of furosemide in combination with NA. The enhancement of urinary sodium excretion during NA treatment suggests that diuretics may reach their site of action more efficiently owing to the improvement in renal perfusion that follows the restoration of splanchnic hemodynamics. This could explain why the natriuretic effect was observed despite a significant reduction in furosemide doses after NA initiation.
Overall, NA was well tolerated. Two patients experienced chest pain, which was firmly attributed to NA administration in one case. In this case, left ventricular segmental hypokinesia occurred during NA administration and resolved after NA withdrawal, and did not recur when NA treatment was resumed at a lower dose. There were no other ischemic adverse effects. In particular, the improvement in serum transaminase activities and the stability of the prothrombin time during the study suggest that NA did not induce hepatic ischemia. Further studies are required to confirm the safety of NA in the treatment of type I HRS. However, it should be stressed that reversal of HRS was obtained at low NA doses (0.8 Ϯ 0.3 mg/h); in addition, the stepwise NA dose increments, combined with the short half-life of this drug, also probably account for the good tolerability observed here.
Although a cost-effectiveness analysis of NA administration was not the aim of this study, the mean cost of a 10-day course of NA is 52 Ϯ 15 euros (47 Ϯ 13 US$), a figure 20-fold lower than the expected cost of a 10-day course of terlipressin that, on a 3 mg/d basis, would have been close to 1,000 euros (900 US$).
In conclusion, this study shows that NA treatment induced systemic vasoconstriction and resulted in reversal of type 1 HRS in a majority of patients, with acceptable safety. These results are similar to those obtained with terlipressin in the treatment of HRS. 9 Prospective studies are therefore required to compare the clinical efficacy, safety, and cost effectiveness of NA and terlipressin in type 1 HRS.
